XNAS · Healthcare · Biotechnology
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.21 | -0.32 | -52.38% | $1.3M | ❌ Miss | +1.38% | +0.92% | — |
| 2026-03-05 | Q4 2025 | -0.30 | -0.87 | -190.00% | $348,000 | ❌ Miss | -2.21% | +17.21% | -2.61% |
| 2025-11-06 |
| Q3 2025 |
| -0.48 |
| -0.55 |
| -14.58% |
| $795,000 |
| ❌ Miss |
| — |
| — |
| — |
| 2024-01-09 | Q3 2024 | -0.03 | -0.22 | -633.33% | $53.6M | ❌ Miss | — | — | — |
| 2023-10-05 | Q2 2024 | — | -0.11 | — | $61.7M | — | -35.29% | -45.13% | -40.27% |
| 2023-07-10 | Q1 2024 | 0.04 | 0.01 | -75.00% | $70.9M | ❌ Miss | -11.80% | -14.47% | -24.55% |
Showing last 6 quarters.